TYK2 lupus strategy faces a trial setback but biomarker path remains open

Alumis' 408-person SLE trial of oral TYK2 inhibitor envudeucitinib missed its primary endpoint, although a higher-interferon subgroup showed stronger improvement and no new safety concerns. The company is considering a late-stage study, but the subgroup signal is exploratory and must be replicated before supporting biomarker-guided development or changing treatment practice.